Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on developing cytisinicline, a potential treatment for nicotine dependence. The company aims to address the global nicotine dependence epidemic by providing a new FDA-approved option for smoking cessation, which has shown effectiveness in clinical trials for helping highly dependent smokers quit. Achieve Life Sciences operates primarily in the United States and Canada, targeting smokers and individuals seeking to overcome nicotine addiction.
